Patient
P2B-002
withdrawn Phase IIA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Sarcoma Oncology Center (Santa Monica, CA) (Dr. Reyes)
consented 2012-02-09
Adverse events
1
Serious AEs
0
Open data queries
1
Luna dropout signal
—
not on Luna
Adverse events 1
Grade 3 alanine aminotransferase increased with onset in cycle 2 (2012-03-18); assessed as related to study drug (possible); resolved 2012-04-05; action: drug interrupted.
Data queries 1
EDC value 120 differs from the EHR: 102 mmHg (Observation/vs-b9c3c2577d57-8480-6-20120226, 2012-02-26; EHR stated 102 mm[Hg]). Confirm against source and correct or explain.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.